Choline Source
Alpha-GPC
Moderate EvidenceShort randomised trials support a cognitive benefit in mild impairment, but the largest safety dataset is observational and points the other way on stroke - which is why this sits at Moderate rather than Strong.
Recommended Dose
300–600 mg daily
Timing
Morning with food, or 30 min before training
Mechanism of Action
Highly bioavailable choline donor that crosses the blood-brain barrier. Converted to acetylcholine, supporting memory encoding, attention, and muscle contraction via cholinergic transmission.
Side Effects & Safety
Headache, dizziness, or GI distress at high doses. May lower blood pressure. Some concern about TMAO conversion with chronic high-dose use.
Do not use / talk to a doctor first
- Prior stroke or TIA, or established cerebrovascular disease
- Existing atherosclerosis or high cardiovascular risk, given the TMAO pathway
- Low blood pressure, or on antihypertensive medication
Interactions
Anticholinergic drugs
Alpha-GPC raises acetylcholine and may blunt their intended effect
Source: mechanistic - cholinergic precursor
Cholinergic and cholinesterase-inhibiting drugs (e.g. donepezil, rivastigmine)
Additive cholinergic load; sweating, salivation, nausea and slowed heart rate become more likely
Source: mechanistic - cholinergic precursor
Antihypertensives
Alpha-GPC can lower blood pressure, so the effects may add up
Source: product safety literature
Scopolamine
Alpha-GPC is used experimentally to reverse scopolamine-induced amnesia, i.e. it directly opposes it
Source: mechanistic - cholinergic precursor
Pregnancy & breastfeeding
No controlled data in pregnancy or breastfeeding. Treat as unknown and avoid.
Who should avoid / see a doctor
Anyone with a history of stroke, TIA or significant cardiovascular disease should not take this without a doctor's involvement - the largest study available reports a materially higher 10-year stroke risk among users, and that finding has not been overturned. Also anyone on cholinergic, anticholinergic or blood-pressure medication.
Synergies
Used in These Stacks
See Alpha-GPC inside a full protocol — the stack pages cover when and why to combine it.
Best Products
Partner offers
Paid placements. We earn a commission if you buy through these links, at no extra cost to you — it does not change what we write. These are the seller’s own products and claims, not ours, and nothing here is medical advice. Speak to a clinician before starting any supplement.
References
- 1.Lee 2021, JAMA Network Open — Among 12,008,977 South Koreans aged 50 or over, alpha-GPC use was associated with a higher 10-year incident stroke risk, adjusted HR 1.46 (95% CI 1.43-1.48); 1.43 (1.41-1.46) in the matched cohort. (observational; the authors note users were older with more comorbidity, so confounding by indication is not excluded)
- 2.Wang 2021, Int J Mol Sci (PMID 34948275) — Alpha-GPC is metabolised to trimethylamine N-oxide, a pro-atherogenic agent - a proposed mechanism for atherosclerosis progression. (preclinical)
- 3.Jeon 2024, BMC Geriatrics (PMID 39300341) — In a 12-week randomised double-blind placebo-controlled trial in amnestic mild cognitive impairment, no serious adverse events occurred and adverse-event rates did not differ from placebo. (short duration - does not address the 10-year stroke signal)
